Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018

As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types. He was kind enough to share his thoughts with us in a video...

ASTRO 2018 Insights: building community, innovating and celebrating strong data around the power of Cesium

Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...

Study Shows Significantly Improved Survival Rate of Cervical Cancer Patients after Receiving Brachytherapy and EBRT

The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer. This study aimed to evaluate the effects on survival rate in patients...

IsoRay Announces First Quarter Fiscal 2019 Financial Results

Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter   RICHLAND, WASHINGTON – November 8, 2018 — IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in...

The value of Cesium for brachytherapy treatment lies in its short half-life for Dr. R. Alex Hsi

Dr. R. Alex Hsi is a Radiation Oncologist at the Peninsula Cancer Center in Poulsbo, Washington. As a practitioner of various prostate radiation treatments like external beam radiation and stereotactic body radiation therapy in addition to brachytherapy, he offers an...